Radiosensitization of human pancreatic cancer cells by MLN4924, an investigational NEDD8-activating enzyme inhibitor

Cancer Research

Volumn 72, Issue 1, 2012, Pages 282-293

  Wei, Dongping ^a   Li, Hua ^a   Yu, Jie ^b   Sebolt, Jonathan T ^a   Zhao, Lili ^a   Lawrence, Theodore S ^a   Smith, Peter G ^b   Morgan, Meredith A ^a   Sun, Yi ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIM PROTEIN; CELL DNA; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; GAMMA HISTONE H2AX; HISTONE H2AX; I KAPPA B ALPHA; MLN 4924; NEDD8 PROTEIN; ORC1 PROTEIN; PROTEIN; PROTEIN NOXA; PROTEIN P21; PROTEIN P27; RADIOSENSITIZING AGENT; REPLICATION LICENSING FACTOR CDT1; SCF E3 UBIQUITIN LIGASE; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; WEE1 PROTEIN;

ANEUPLOIDY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER MODEL; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULLIN NEDDYLATION; DNA DAMAGE; DRUG EFFICACY; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IONIZING RADIATION; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; RADIATION DOSE; RADIOSENSITIZATION; RNA INTERFERENCE; TUMOR VOLUME; TUMOR XENOGRAFT;

ANEUPLOIDY; ANIMALS; BASE SEQUENCE; CELL DIVISION; CELL LINE, TUMOR; CYCLOPENTANES; DNA DAMAGE; ENZYME INHIBITORS; FLUORESCENT ANTIBODY TECHNIQUE; G2 PHASE; HUMANS; PANCREATIC NEOPLASMS; PYRIMIDINES; RADIATION TOLERANCE; RNA, SMALL INTERFERING; UBIQUITINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84855411991     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-2866     Document Type: Article

References (50)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Sharma C, Eltawil KM, Renfrew PD, Walsh MJ, Molinari M. Advances in diagnosis, treatment and palliation of pancreatic carcinoma: 1990-2010. World J Gastroenterol 2011;17:867-97.
3. Iacobuzio-Donahue CA, Fu B, Yachida S, Luo M, Abe H, Henderson CM, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol 2009;27:1806-13.
4. Loehrer PJ, Powell ME, Cardenes HR, Wagner L, Brell JM, Ramanathan RK, et al. A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201. J Clin Oncol 2008; ASCO Meeting Abstracts May 20 4506.
5. Ben-Josef E, Griffith K, Francis IR, Khan G, Lawrence T, Abrams R, et al. Phase I radiation dose-escalation trial of intensity-modulated radiotherapy (IMRT) with concurrent fixed dose-rate gemcitabine (FDR-G) for unresectable pancreatic cancer. J Clin Oncol 2009;27:15s (suppl; abstr 4602).
6. Morgan MA, Parsels LA, Zhao L, Parsels JD, Davis MA, Hassan MC, et al. Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. Cancer Res 2010;70:4972-81.
7. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-6. (Pubitemid 46972777)
8. Morgan MA, Parsels LA, Kollar LE, Normolle DP, Maybaum J, Lawrence TS. The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer. Clin Cancer Res 2008;14:5142-9.
9. Jia L, Bickel JS, WuJ, Morgan MA, Li H, Yang J, et al. RBX1 (RING-box protein 1) E3 ubiquitin ligase is required for genomic integrity by modulating DNA replication licensing proteins. J Biol Chem 2011;286:3379-86.
10. Jia L, Yang J, Hao X, Zheng M, He H, Xiong X, et al. Validation of SAG/ RBX2/ROC2 E3 ubiquitin ligase as an anticancer and radiosensitizing target. Clin Cancer Res 2010;16:814-24.
11. Deshaies RJ, Joazeiro CA. RING domain E3 ubiquitin ligases. Annu Rev Biochem 2009;78:399-434.
12. Nakayama KI, Nakayama K. Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer 2006;6:369-81.
13. Soucy TA, Smith PG, Milhollen MA, Berger AJ, Gavin JM, Adhikari S, et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 2009;458:732-6.
14. Wu K, Fuchs SY, Chen A, Tan P, Gomez C, Ronai Z, et al. The SCF (HOS/beta-TRCP)-ROC1 E3 ubiquitin ligase utilizes two distinct domains within CUL1 for substrate targeting and ubiquitin ligation. Mol Cell Biol 2000;20:1382-93. (Pubitemid 30069258)
15. Sun Y. E3 ubiquitin ligases as cancer targets and biomarkers. Neoplasia 2006;8:645-54. (Pubitemid 44379791)
16. Duda DM, Borg LA, Scott DC, Hunt HW, Hammel M, Schulman BA. Structural insights into NEDD8 activation of cullin-RING ligases: conformational control of conjugation. Cell 2008;134:995-1006.
17. Saha A, Deshaies RJ. Multimodal activation of the ubiquitin ligase SCF by Nedd8 conjugation. Mol Cell 2008;32:21-31.
18. Goldenberg SJ, Cascio TC, Shumway SD, Garbutt KC, Liu J, Xiong Y, et al. Structure of the Cand1-Cul1-Roc1 complex reveals regulatory mechanisms for the assembly of the multisubunit cullin-dependent ubiquitin ligases. Cell 2004;119:517-28. (Pubitemid 39482351)
19. Kamura T, Conrad MN, Yan Q, Conaway RC, Conaway JW. The Rbx1 subunit of SCF and VHL E3 ubiquitin ligase activates Rub1 modification of cullins Cdc53 and Cul2. Genes Dev 1999;13:2928-33.
20. Xirodimas DP. Novel substrates and functions for the ubiquitin-like molecule NEDD8. Biochem Soc Trans 2008;36:802-6.
21. Jia L, Soengas MS, Sun Y. ROC1/RBX1 E3 ubiquitin ligase silencing suppresses tumor cell growth via sequential induction of G2-M arrest, apoptosis, and senescence. Cancer Res 2009;69:4974-82.
22. Tan M, Zhu Y, Kovacev J, Zhao Y, Pan ZQ, Spitz DR, et al. Disruption of Sag/Rbx2/Roc2 induces radiosensitization by increasing ROS levels and blocking NF-kB activation in mouse embryonic stem cells. Free Radic Biol Med 2010;49:976-83.
23. Zheng M, Morgan-Lappe SE, Yang J, Bockbrader KM, Pamarthy D, Thomas D, et al. Growth inhibition and radiosensitization of glioblastoma and lung cancer cells by small interfering RNA silencing of tumor necrosis factor receptor-associated factor 2. Cancer Res 2008;68:7570-8.
24. Fertil B, Dertinger H, Courdi A, Malaise EP. Mean inactivation dose: a useful concept for intercomparison of human cell survival curves. Radiat Res 1984;99:73-84. (Pubitemid 14095136)
25. Zhao L, Morgan MA, Parsels LA, Maybaum J, Lawrence TS, Normolle D. Bayesian hierarchical changepoint methods in modeling the tumor growth profiles in xenograft experiments. Clin Cancer Res 2011;17:1057-64.
26. Begg AC, Stewart FA, Vens C. Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer 2011;11:239-53.
27. Skaar JR, D'Angiolella V, Pagan JK, Pagano M. SnapShot: F Box Proteins II. Cell 2009;137:1358, e1.
28. Liontos M, Koutsami M, Sideridou M, Evangelou K, Kletsas D, Levy B, et al. Deregulated overexpression of hCdt1 and hCdc6 promotes malignant behavior. Cancer Res 2007;67:10899-909. (Pubitemid 350145919)
29. Heald R, McLoughlin M, McKeon F. Human wee1 maintains mitotic timing by protecting the nucleus from cytoplasmically activated Cdc2 kinase. Cell 1993;74:463-74. (Pubitemid 23244612)
30. Parker LL, Piwnica Worms H. Inactivation of the p34cdc2-cyclin B complex by the human WEE1 tyrosine kinase. Science 1992;257:1955-7.
31. Jia L, Sun Y. SCF E3 ubiquitin ligases as anticancer targets. Current Cancer Drug Targets 2011;11:347-56.
32. Sun Y. Targeting E3 ubiquitin ligases for cancer therapy. Cancer Biol Therapy 2003;2:623-9.
33. Wei D, Sun Y. Small RING finger proteins RBX1 and RBX2 of SCF E3 ubiquitin ligases: the role in cancer and as cancer targets. Genes & Cancer 2010;1:700-7.
34. Sun Y. Overview of approaches for screening for ubiquitin ligase inhibitors. Methods Enzymol 2005;399:654-63. (Pubitemid 41772759)
35. Brownell JE, Sintchak MD, Gavin JM, Liao H, Bruzzese FJ, Bump NJ, et al. Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ. Mol Cell 2010;37:102-11.
36. Swords RT, Kelly KR, Smith PG, Garnsey JJ, Mahalingam D, Medina E, et al. Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia. Blood 2010;115:3796-800.
37. Milhollen MA, Traore T, Adams-Duffy J, Thomas MP, Berger AJ, Dang L, et al. MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF- {kappa}B-dependent lymphoma. Blood 2010;116:1515-23.
38. Lin HK, Chen Z, Wang G, Nardella C, Lee SW, Chan CH, et al. Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature 2010;464:374-9.
39. Jia L, Li H, Sun Y. Induction of p21-dependent senescence by an NAE inhibitor, MLN4924, as a mechanism of growth suppression. Neoplasia 2011;13:561-9.
40. Lin JJ, Milhollen MA, Smith PG, Narayanan U, Dutta A. NEDD8- targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells. Cancer Res 2010;70:10310-20.
41. Soucy TA, Smith PG, Rolfe M. Targeting NEDD8-activated cullin-RING ligases for the treatment of cancer. Clin Cancer Res 2009;15:3912-6.
42. Arias EE, Walter JC. Strength in numbers: preventing rereplication via multiple mechanisms in eukaryotic cells. Genes Dev 2007;21:497-518. (Pubitemid 46409465)
43. Dutta A. Chaotic license for genetic instability and cancer. Nat Genet 2007;39:10-1. (Pubitemid 46026494)
44. Rialland M, Sola F, Santocanale C. Essential role of human CDT1 in DNAreplication and chromatin licensing. J Cell Sci 2002;115:1435-40. (Pubitemid 34428701)
45. Mehrotra S, Maqbool SB, Kolpakas A, Murnen K, Calvi BR. Endocycling cells do not apoptose in response to DNA rereplication genotoxic stress. Genes Dev 2008;22:3158-71.
46. Milhollen MA, Narayanan U, Soucy TA, Veiby PO, Smith PG, Amidon B. Inhibition of NEDD8-activating enzyme induces rereplication and apoptosis in human tumor cells consistent with deregulating CDT1 turnover. Cancer Res 2011;71:3042-51.
47. Wang Y, Jacobs C, Hook KE, Duan H, Booher RN, Sun Y. Binding of 14-3-3beta to the carboxyl terminus of Wee1 increases Wee1 stability, kinase activity, and G2-M cell population. Cell Growth Differ 2000;11:211-9. (Pubitemid 30211010)
48. Li J, Wang Y, Sun Y, Lawrence TS. Wild-type TP53 inhibits G(2)-phase checkpoint abrogation and radiosensitization induced by PD0166285, a WEE1 kinase inhibitor. Radiat Res 2002;157:322-30. (Pubitemid 34263846)
49. Wang Y, Li J, Booher RN, Kraker A, Lawrence T, Leopold WR, et al. Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator. Cancer Res 2001;61:8211-7. (Pubitemid 33091614)
50. Watanabe N, Arai H, Nishihara Y, Taniguchi M, Hunter T, Osada H. M-phase kinases induce phospho-dependent ubiquitination of somatic Wee1 by SCFbeta-TrCP. Proc Natl Acad Sci U S A 2004;101:4419-24. (Pubitemid 38437427)